Further, to elucidate the mode of action of TGF-β and it’s abilities to induce tumor aggressiveness depending on the levels of pVHL expression, we utilized two ccRCC cell lines A498 (VHL-/-) and ACHN (VHL+/+) for in-vitro studies. The gene discussed is VHL; the disease is nonpapillary renal cell carcinoma.